Apple: Jobs Isn't Sick, Says Argus Research

Pretty much nobody is picking up the phone at equity research firm Argus Research this morning, so take this as unverified: The firm’s analyst on Apple (AAPL), Wendy Abramowitz, this morning lowered her price target on Apple to $145 from $155, while affirming that she does not believe Apple CEO Steve Jobs’s health is deteriorating, as had been the speculation of a post on gadget site Gizmodo on Tuesday. Abramowitz lowered her earnings estimate for Apple for the December-ended fiscal Q1, from $10.1 billion and $1.54 in EPS to $9.7 billion and $1.52, which appears to have mainly to do with the fact that December’s margins will be lower than the December quarter of 2007 when the company was riding the release of the Leopard operating system.

Read the rest of this post